We investigated the effects of highmonounsaturated fatty acid (MUFA) versus high-carbohydrate enteral formula on post-prandial plasma glucose concentration and insulin response in Japanese patients with type 2 diabetes mellitus and healthy Japanese volunteers. Ten healthy volunteers aged 20.8 ± 1.2 years and 12 diabetic patients with good glycaemic control (glycosylated haemoglobulin < 7%) aged 58.6 ± 7.7 years were randomly assigned to take high-MUFA or high-carbohydrate formula after a 12-h overnight fast. The patients switched to the other formula after 7 days. Post-prandial plasma glucose and insulin response were significantly lower in all subjects after taking high-MUFA formula compared with high-carbohydrate formula. No differences were observed in free fatty acids, triglycerides and plasma glucagon between the two diet groups. In conclusion, a high-MUFA enteral formula suppresses post-prandial hyperglycaemia without exaggerated insulin secretion compared with a high-carbohydrate enteral diet in patients with type 2 diabetes and healthy subjects.
Introduction
The number of patients who receive tube feeding is increasing in Japan in step with the ageing population. 1 It is, therefore, essential to consider the composition of enteral nutrition formulas and their effects on glucose and lipids parameters, especially in patients with compromised metabolic function such as diabetics. 2 Much clinical attention has been paid to liquid enteral formulas with certain compositions since these might cause elevation of plasma J Yokoyama, Y Someya, R Yoshihara et al. High-MUFA vs high-carbohydrate formula in diabetes glucose levels, leading to a risk of worsening diabetes mellitus or poorer control of plasma glucose in diabetic patients. 3 -5 A new enteral nutritional formula, Glucerna ® (Abbott Japan Co., Ltd, Tokyo, Japan), containing reduced carbohydrate, modified fat and a high concentration (34.3%) of monounsaturated fatty acid (MUFA), has been developed to attenuate post-prandial blood glucose elevation in diabetic individuals. Several clinical studies in western countries have suggested beneficial effects of taking this formula on glycaemic control in patients with diabetes mellitus. 6 -8 No detailed study has yet been conducted, however, on the course of plasma glucose concentration and the effects on insulin or glucagon secretion following intake of this high-MUFA enteral formula. The aim of the present study, therefore, was to investigate the effects on plasma glucose concentration and insulin secretion of the high-MUFA nutritional formula, Glucerna ® , in healthy Japanese volunteers and patients with diabetes mellitus in comparison with a commonly used high-carbohydrate enteral formula, Enrich ® -SF (Meiji Milk Co., Ltd, Tokyo, Japan).
Patients and methods

PARTICIPANTS
Healthy volunteers and patients with type 2 diabetes mellitus with good glycaemic control were recruited. Inclusion criteria for the healthy individuals were no history of gastrointestinal disorder and impaired glucose tolerance, fasting plasma glucose concentration < 110 mg/dl, and no abnormality of renal function. Patients with type 2 diabetes mellitus were required to have good control of plasma glucose, defined as glycosylated haemoglobin (HbA 1c ) < 7.5% and they had to be < 65 years of age. Those with compromised hepatic or renal function and a history of gastrointestinal disorders, and those who had previously received insulin therapy were excluded.
The study was approved by the ethical committee of Jikei Daisan University Hospital. All subjects provided written informed consent to participate prior to inclusion in the study.
STUDY DESIGN
This was a randomized, crossover designed study. Participants were randomly assigned to take either high-MUFA formula (Glucerna ® ; 255 kcal/250 ml) or highcarbohydrate formula (Enrich ® -SF; 250 kcal/250 ml). After 7 days they were crossed over to receive the formula on the other study arm. Table 1 shows the nutritional composition of the two formulas.
During the study period, subjects were instructed not to take alcohol or soft drinks, and were advised to avoid strenuous exercise and regularly to eat three meals every day. On day 1 after a 12-h overnight fast, blood samples were obtained at 09:00 h and all subjects then ingested a single 250 ml can of either of the test formulas over about a 5min period. Blood samples were again collected at 30, 60, 90, 120 and 180 min after ingestion of formula. At 7 days after the first intake, each subject repeated the same process with the other formula. Adverse events were recorded throughout the study by the participating physicians.
CLINICAL ASSESSMENTS
Plasma glucose, serum immunoreactive insulin (IRI), serum free fatty acid (FFA), serum triglyceride and plasma immunoreactive glucagon (IRG) concentrations were assessed at each timepoint. Plasma glucose was measured by the glucose oxidase method in an autoanalyser (Hitachi Type 7170; Hitachi Co., Tokyo, Japan). IRI was measured by the two-step sandwich enzyme immunoassay method using the Eiken Insulin Kit ® (Eiken Kagaku Co., Tokyo, Japan). IRG was determined by the double-antibody radioimmunoassay method using the Glucagon kit Daiichi II (SRL Co., Ltd, Tokyo, Japan).
STATISTICAL ANALYSIS
Student's t-test was employed for statistical analysis of the data. All values are expressed as mean ± SD and statistical significance was defined at P < 0.05. 
Results
PARTICIPANTS
OUTCOME IN HEALTHY CONTROLS
Plasma glucose concentration 30 min after intake of the high-MUFA formula was significantly lower among healthy individuals than at 30 min after intake of the high-carbohydrate formula (P < 0.01; Fig.  1 ). Serum IRI concentration measured at 30, 60 and 90 min after intake was significantly lower (P < 0.05, P < 0.01 and P < 0.05, respectively) in the high-MUFA formula group than in the high-carbohydrate formula group in healthy participants, as shown in Fig. 2 .
The area under the curve of plasma glucose for 0 -180 min after intake (AUC 0 -180 min ) was significantly lower in the high-MUFA formula group than in the high-carbohydrate formula group (P < 0.05). The AUC 0 -180 min of serum insulin was also significantly lower in the high-MUFA formula group than in the high-carbohydrate formula group (P < 0.01). The ratio of insulin AUC 0 -180 min to plasma glucose AUC 0 -180 min was significantly lower in the high-MUFA formula group than in the high-carbohydrate formula group (P < 0.01; Table 2 ).
There was no significant difference in serum FFA, serum triglyceride and plasma IRG between the two enteral formula study groups over the course of the study period ( Fig. 3 ).
Following intake of either of the two formulas, no adverse events, including gastrointestinal symptoms and laboratory abnormalities, were observed.
OUTCOME IN TYPE 2 DIABETES MELLITUS PATIENTS
In patients with type 2 diabetes mellitus, plasma glucose reached a peak at 60 min after intake of both formulas, although was significantly lower in patients given the high-MUFA formula over this period than in those given the high-carbohydrate formula (P < 0.01, P < 0.001 and P < 0.01 at 30, 60 and 90 min, respectively; Fig. 4 ). By 180 min, however, the plasma glucose levels in both groups had fallen back to approximately C what they were at baseline, although the level in the high-MUFA formula group was significantly higher (P < 0.05) than in the high-carbohydrate formula group.
Serum IRI was significantly lower at 30, 60 and 90 min after intake of the high-MUFA formula as compared with IRI at the corresponding times after intake of the highcarbohydrate formula (P < 0.05, P < 0.01 and P < 0.05, respectively), as shown in Fig. 5 .
The AUC 0 -180 min of plasma glucose was significantly lower in the high-MUFA formula group than in the highcarbohydrate formula group in patients with type 2 diabetes mellitus (P < 0.01), as also was the AUC 0 -180 min of insulin (P < 0.01). The ratio of insulin to plasma glucose AUC 0 -180 min was significantly lower in the high-MUFA formula group than in the high-carbohydrate formula group (P < 0.01; Table 2 ). There were no significant differences for FFA, serum triglyceride and IRG between the two enteral formula groups (Fig. 6) .
No adverse events, including no gastrointestinal symptoms and no laboratory abnormalities, were observed following intake of either formula.
Discussion
It has been reported that the absorption rate of nutrients, such as carbohydrate and fat, differs between liquid and solid diets, with a liquid diet passing through the stomach about twice as rapidly as a solid diet. 9 In another study of liquid versus solid diets, plasma glucose reached a peak 30 min after intake of high-carbohydrate liquid formula, whereas it rose slowly after intake of the solid formula, suggesting that intake of the liquid formula led to a more marked rise in plasma glucose and higher insulin secretion versus solid formula. 10 Liquid enteral formulas rich in carbohydrate may, therefore, cause plasma glucose concentration to rise sharply, potentially making it more difficult to control in diabetic patients in whom glucose tolerance is impaired.
The liquid enteral formula Glucerna ® used in this study is a high-fat and reducedcarbohydrate formula that was developed to avoid a rapid rise in plasma glucose concentration by replacing carbohydrate content with fat. 6 This enteral formula provides 49.3% of energy as fat, 34.3% as carbohydrate and 16.4% as protein. It is a sucrose-free high-MUFA enteral formula in which oleic acid (a typical MUFA) accounts for 69.7% of the fatty acids contained. Although Glucerna ® is rich in fat, the predominance of oleic acid means that its long-term use is unlikely to cause adverse effects on metabolism due to excessive fat intake. Rather, improvement of plasma glucose control and lipid metabolism after prolonged intake of this formula has been reported. 8 C High-MUFA vs high-carbohydrate formula in diabetes saturated fatty acids account for a high percentage of dietary fat. 11 Large-scale epidemiological studies have shown that MUFA does not adversely affect lipid metabolism and is unlikely to stimulate atherosclerosis. 12 -15 Clinical studies have also indicated that a high-MUFA diet is more favourable than a high-carbohydrate diet for plasma glucose control, stimulation of insulin secretion and lipid metabolism in patients with type 2 diabetes mellitus. 16, 17 It is difficult for diabetic patients who have impaired glucose metabolism to utilize ingested carbohydrate. Post-prandial glucose level has been suggested to be the most important index of glycaemic control in diabetic patients, and elevated post-prandial glucose is associated with increased cardiovascular complications and cardiovascular mortality. 18, 19 Although recent advances in drug therapy have made it possible to control post-prandial hyperglycaemia to some extent, intake of a highcarbohydrate liquid diet is likely to induce marked hyperglycaemia. Post-prandial hyperglycaemia and excessive stimulation of insulin secretion due to a high-carbohydrate diet are associated with obesity and are unfavourable for preventing cardiovascular disease in non-insulin-resistant individuals as well as in diabetic patients. 20 -22 A high-MUFA enteral formula, which suppresses post-prandial hyperglycaemia and does not excessively stimulate insulin secretion in patients with type 2 diabetes mellitus is, therefore, promising as a means of improving the health of diabetic patients and preventing development of cardiovascular diseases.
Glucerna ® is a useful dietary formula for diabetic patients unable to ingest a solid diet since, as shown in the present study, it suppresses post-prandial elevation of plasma glucose concentration and thereby reduces the burden on pancreatic β-cells. The present study suggests, therefore, that this high-MUFA enteral formula is useful for Japanese patients with diabetes. It also shows it to be safe and to provide satisfactory nutritional replenishment while keeping plasma glucose concentration stable in patients who are unable adequately to ingest solid food, unlike high-carbohydrate, low-fat formulas which are known to cause post-prandial hyperglycaemia. 3 We conclude that a high-MUFA liquid diet may suppress post-prandial elevation of plasma glucose concentration and reduce the burden on pancreatic β-cells in healthy and diabetic Japanese individuals who are not accustomed to eating a high-fat diet compared with a high-carbohydrate liquid diet. It is our hope that these results will contribute to awareness of recommending a high-MUFA diet when giving dietary advice to patients with type 2 diabetes mellitus.
